
from Top Lifestyle News- News18.com https://ift.tt/3ak5CiW
TATA Group's newly launched medical venture Tata Medical & Diagnostics is reportedly in talks with Moderna to bring its COVID-19 vaccine to India after conducting clinical trials to ensure its safety and efficacy. The Economic Times reported that the dialogue is still in its early days and that sources have said that the company would partner up with the Council of Scientific & Industrial Research (CSIR) to carry out the necessary clinical trials of Moderna’s vaccine candidate in India.
The Director-General of CSIR Shekhar C Mande told The Print, "We are in talks with Moderna to understand the science behind their vaccine and how it works on the human body. Till now, the discussions are scientific in nature".
The Centre for Cellular and Molecular Biology (CCMB) in Hyderabad has the capacity to develop this vaccine very quickly – within weeks, Mande said.
When asked about Indian pharma companies interested in, Mande said “I don’t know if Wockhardt has shown interests or even if Tata Sons has pitched in. We have worked with Tata Sons in the past. We will be delighted if they are interested to take part in this. Also, IIL could work.”
So even though Moderna's vaccine has been approved by the US, UK and France and is being used in inoculation drives around the world, it is still important that the vaccine is tested in India. This is because not everyone will respond to a vaccine in the same way and that applies to people from the same race and even more so for people from different races. Health authorities need country-specific data to give their approvals and ensure the vaccine will not have any adverse effects on their people.
The bridge trial, as it is called, gives a country access to a vaccine that otherwise would've taken a long time to reach them. This is an important aspect especially in a crisis situation like COVID-19.
This is also the reason Russia's COVID-19 vaccine Sputnik V needs to complete a Phase 3 trial and have partnered up with Hyderabad's pharma company Dr Reddy's and why AstraZeneca tied up with Serum Institute of India to conduct the Oxford vaccine trials and produce it in India. Johnson & Johnson have also tied up Biological E to conduct a trial in India.
The other reason, according to a Reuters report, is that India has made it mandatory for any vaccine maker to conduct a clinical trial in the country before it will get a chance to be approved.
According to the ET report, "exploratory talks have started between Tata Medical & Diagnostics and Moderna and concrete plans will be finalised once government approvals for private sector participation come in".
India has approved two COVID-19 vaccines – Bharat Biotech's Covaxin and Serum Institute of India's Covishield – for emergency use. According to NITI Aayog Member Dr VK Paul, India has six vaccine clinical trials that are currently going on in the country.
The Moderna vaccine is based on mRNA technology and evidence from its clinical trials for its COVID-19 vaccine shows that it was 94 percent effective at preventing lab-confirmed COVID-19 in people who were given two doses and had no history of the infection. Moderna's vaccine candidate 'mRNA-1273' is believed to offer protection against the virus for 'several months' according to World Health Organisation (WHO) but according to the company's CEO Stephane Bancel, immunity against the vaccine can last for a couple of years.
The vaccine is given in two doses 28 days apart and can be extended to 42 days. It has shown to be effective around 14 days after one receives the first dose. The vaccine needs to be kept frozen between -25°C and -15°C, which is similar to a normal freezer if it’s not being used immediately. Each vial contains enough doses to vaccinate 10 people. According to a Time report, the vaccines needs to be thawed before it is used and once thawed, the unopened vial needs to be used within 30 days. Once a vial is punctured, it needs to be used within six hours.
The vaccine was not tested in pregnant or breastfeeding women and more studies need to be conducted to know if it is safe for them. The US's Centre for Disease Control (CDC) said it is a woman's personal choice. The vaccine is also not supposed to be given to children under the age of 18 years as those studies are needed to be conducted as well.
According to the clinical trial data, WHO says the vaccine is safe and effective in people with known medical conditions hypertension, diabetes, asthma, pulmonary, liver or kidney disease, as well as chronic infections that are stable and controlled.
The most common side effects, according to the CDC, from getting the vaccine are pain in the arm you got the shot along with swelling and redness. Other effects throughout the body are chills, tiredness and headache.
As the demand for the COVID-19 vaccine intensified around the world, China said that it has increased the number of vaccines undergoing clinical trials to 16 from 11 to step up supplies at home and abroad. China is conducting clinical trials of 16 COVID-19 vaccines, seven of which have entered phase-III trials and one has conditionally hit the market, Wu Yuanbin, an official with the Ministry of Science and Technology, was quoted as saying by the state-run CGTN TV.
Wu made the comments during a haematology conference on Saturday.
Yang Sheng, Deputy Director of China's National Medical Products Administration's drug registration bureau, said last month that a total of 11 Chinese vaccine candidates are in different stages of testing at home and abroad.
Currently, China is vaccinating people at home and some countries abroad with two vaccines. The Chinese government has given conditional approval to Sinopharm while the results of the phase-3 trial is yet to be released.
The World Health Organisation (WHO) is reviewing the trials of both the vaccines.
China has said that so far 46 countries have expressed their desire to import the China-made vaccines.
Respiratory-disease expert Zhong Nanshan said on Sunday that the mass inoculation of homegrown COVID-19 vaccines underway in China shows the vaccines are safe and effective.
The two vaccines currently in use in China – the China National Biotec Group (CNBG) COVID-19 vaccine and the CoronaVac vaccine developed by China's Sinovac Biotech Ltd – are both inactivated vaccines that are relatively safe, Zhong said at the launch ceremony of an event in south China's Guangdong province.
According to the Chinese Centre for Disease Control and Prevention (China CDC), more than 24 million doses of the COVID-19 vaccine had been administered in China till Sunday, state-run Xinhua news agency reported.
"The rate of the vaccines' mild adverse reactions, which include fever, soar arms and other symptoms, is six per 100,000 people," Zhong said.
The rate of severe adverse vaccine reactions is one in a million, only one third of that of flu vaccines, he said.
NASA leaders, retired launch directors, families of fallen astronauts and space fans marked the 35th anniversary of the Challenger disaster on Thursday, vowing never to forget the seven who died during liftoff. The pandemic kept this year’s remembrance more muted than usual. Barely 100 people — all masked and seated or standing far apart — gathered in front of Kennedy Space Center’s Space Mirror Memorial. The late morning ceremony was held almost exactly the same time as the accident shortly after liftoff on 28 January 1986.
Among the attendees: Donna Smith, visiting from Florida’s Gulf Coast to “make sure they’re never forgotten.” She was a high school student when the crew was lost; the sky was so clear that frigid morning that she could see the doomed launch all the way across the state.
The widow of Challenger commander Dick Scobee quietly observed the anniversary from her home in Chattanooga, Tennessee. In a recent interview, June Scobee Rodgers said the presence of teacher Christa McAuliffe on the flight added to the crew’s lasting legacy. Scobee Rodgers, herself a longtime educator, said her husband was assigned the teacher-in-space flight because of her own career. NASA figured “he would have compassion for a teacher,” she told The Associated Press.
A social studies teacher in Concord, New Hampshire, McAuliffe was going to perform experiments and offer lessons from space.
Scobee Rodgers helped establish the Challenger Center for Space Science Education in the wake of the accident, along with the other Challenger families. She said that helped all of them heal and “move forward.”
“In their loss, somehow, their mission continues in many, many different ways,” she said.
Flags flew half-staff at NASA centres around the country Thursday, with small ceremonies also held at Johnson Space Center in Houston and Arlington National Cemetery in Virginia. The US Mint is offering a new commemorative silver dollar honouring McAuliffe.
This year’s observance focused on the Challenger crew — McAuliffe, Scobee, Michael Smith, Judith Resnik, Ellison Onizuka, Ronald McNair and Gregory Jarvis. But it also paid tribute to the 18 others whose names are carved into the massive granite mirror at Kennedy’s visitor complex.
Seven were killed during reentry aboard shuttle Columbia on 1 February 2003. Three died in the Apollo 1 fire on the launch pad on 27 January 1967. Another was killed in a Virgin Galactic test flight in 2014. Plane crashes claimed the rest.
“We honour these heroes and remind ourselves of the lessons that the past continues to teach us,” said Kennedy’s deputy director, Janet Petro.
Petro noted that SpaceX is now flying astronauts to the International Space Station for NASA, and more new spaceships are on the horizon. Many of the newcomers were not around for the shuttle accidents, she said, and so the hard lessons must be shared.
Poor management and a stifling culture contributed to both shuttle accidents. Challenger was brought down by eroded O-ring seals in the right solid rocket booster, Columbia by a chunk of foam insulation that broke off the fuel tank at liftoff and pierced the left-wing.
Retired launch director Mike Leinbach — who was at Kennedy for both shuttle tragedies — said his one wish is for no more names to be added to the memorial.
“It’s already too full.”
Xiaomi says on Sunday it has filed a lawsuit seeking to overturn the former Trump administration's last-minute blacklisting of the electronics giant. Xiaomi said it filed the appeal with a Washington federal court Friday after former president Donald Trump's administration barred investment in the firm, saying the Beijing-headquartered company was a part of the Chinese military. Xiaomi said it "believes that the decision ... was factually incorrect and has deprived the company of legal due process."
"With a view to protect the interest of its global users, partners, employees and shareholders, Xiaomi Corporation has filed proceedings in the United States District Court for the District of Columbia against the Department of Defense and Department of Treasury of the United States, for listing the company as “Communist Chinese Military Company," the statement added.
Just six days before Trump left office, his officials made a series of announcements targeting Xiaomi and other Chinese firms including state oil giant CNOOC and embattled social media favourite TikTok.
Xiaomi – which overtook Apple last year to become the world's third-largest smartphone manufacturer – was one of nine firms the Pentagon classified as "Communist Chinese military companies." As per the executive order signed by Trump, after the ban, US investors had to divest their stakes in Chinese companies on the military list by November 2021.
The measure was seen as an attempt to cement Trump's trade war legacy with China after four years of turbulent relations with Beijing.
The blacklisting means US investors cannot buy Xiaomi securities.
The company's stock price dropped more than 10 percent following the blacklisting.
With inputs from AFP
Netflix, for Android devices, could soon be getting a new time feature. The company has been testing a sleep timer that would stop the video playback on its own, after a set time limit. This story is available on The Verge website. This new feature will allow users to choose between four timer settings that include a 15 minutes timer, 30 minutes timer, 45 minutes timer, or end of whatever they are watching. As soon as the time limit comes to an end the app would automatically stop.
Theoretically, this feature will aid in saving battery in Android devices, while making sure that the episodes don't continue via auto-play.
For now, the test is limited to selected Android users but Netflix could bring this feature to other devices like desktops, TV sets, depending on how widely the product is used.
[hans][hstep]Step 1:Select your favorite TV show or movie on your mobile device[/hstep]
[hstep]Step 2: Users will see a clock icon on the upper right labeled as Timer[/hstep]
[hstep]Step 3: Click on the Timer[/hstep]
[hstep]Step 4: Now select from the 15, 30, 45 minutes, or Finish Show options[/hstep][/hans]
The feature, for now, is only available for adult profiles. The new screen time option feature could be a great option for kids too and the company could potentially make a version of the same or account profiles designed for children, depending on how well the feature is received. Instead of tapping on the clock icon and setting the timer, the feature for kids should be tweaked a little, as kids tend to tap on screens frequently.
This seems like a pretty cool feature, especially if you are someone, who falls asleep watching Netflix or other content on the phone. Having a turn-off option when an episode ends seems like a great feature.
A Maine company that’s developing a rocket to propel small satellites into space passed its first major test on Sunday. Brunswick-based bluShift Aerospace launched a 20-foot (6-meter) prototype rocket, hitting an altitude of a little more than 4,000 feet (1,219 meters) in a first run designed to test the rocket’s propulsion and control systems. It carried a science project by Falmouth High School students that will measure flight metrics such as barometric pressure, a special alloy that’s being tested by a New Hampshire company — and a Dutch dessert called stroopwafel, in an homage to its Amsterdam-based parent company.
Organizers of the launch said the items were included to demonstrate the inclusion of a small payload.
The company, which launched from the northern Maine town of Limestone, the site of the former Loring Air Force Base, is one of dozens racing to find affordable ways to launch so-called nano satellites. Some of them, called Cube-Sats, can be as small as 10 centimeters by 10 centimeters.
Sascha Deri, chief executive officer of bluShift, said the company is banking on becoming a quicker, more efficient way of transporting satellites to space.
“There’s a lot of companies out there that are like freight trains to space,” Deri said. “We are going to be the Uber to space, where we carry one, two or three payloads profitably.”
Another aspect that makes bluShift’s rocket different is its hybrid propulsion system.
It relies on a solid fuel and a liquid oxidizer passing either through or around the solid fuel; the result is a simpler, more affordable system than a liquid fuel-only rocket, said spokesperson Seth Lockman. The fuel is a proprietary biofuel blend sourced from farms, Deri said.
“It’s a very nontoxic fuel, I like to say that I could give it to either one of my little daughters. Nothing bad would happen to them, I swear,” he said. “So it’s very much nontoxic. It’s carbon neutral.”
The goal is to create a small rocket that could launch a 30-kilogram (66-pound) payload into low-Earth orbit, more than 100 miles (160 kilometers) above Earth’s surface. Lockman said orbit could be possible by 2024.
The company has spent $800,000 on research and development, with some of the money coming from NASA.
Representatives from bluShift said they don’t anticipate being able to launch from Brunswick, where they are headquartered, because of population density in the area.
An attempted test launch in Limestone earlier in January was postponed because of weather. Sunday’s launch was also held back by a couple of false starts, but event organizers described the eventual 3 p.m. liftoff as “perfect.”
Poco has officially announced on Twitter and has sent out invites for the Poco M3 launch tomorrow (2 February). Poco has released a teaser video revealing that the smartphone houses a huge rectangular camera module at the back. It is also confirmed that Poco M3 will be available in black, blue and yellow colour options. Poco M3 had previously debuted in globally last year in November. The India launch will take place at 12 pm tomorrow.
Images that will stop the scroll! Get ready for likes, more likes and a lot more likes.#POCOM3 with 48MP triple camera set-up is launching on 2nd Feb.
Learn more: https://t.co/npDCHk8hUD pic.twitter.com/WiCMSGa0OR
— POCO India #POCOM3 (@IndiaPOCO) January 30, 2021
Going by the global variant, Poco M3 will feature a 6.53-inch full-HD+ display that comes with 1,080 x 2,340 pixels resolution. It is likely to be powered by Snapdragon 662 chipset and offers 4 GB RAM and up to 128 GB of internal storage. It is expected to be powered by MIUI 12 based on Android 10. It will also feature a side-mounted fingerprint sensor.
For photography, it might sport a triple rear camera setup that houses a 48 MP primary sensor, a 2 MP secondary sensor and a 2 MP depth sensor. For selfies, it might come with an 8 MP front camera.
As for the battery, it is likely to be equipped with a 6,000 mAh battery that supports 18 W fast charging.